The Rediscovery of DON (6-Diazo-5-oxo-L-norleucine)

  • D. L. Kisner
  • R. Catane
  • F. M. Muggia
Part of the Recent Results in Cancer Research book series (RECENTCANCER, volume 74)

Summary

DON (6-diazo-5-oxo-l-norleucine) and azotomycin are glutamine antagonists that were tested in human malignancies in the 1950s. Azotomycin demonstrated significant activity in colorectal cancer. DON is probably the active form of azotomycin. Recent impressive results for both of these agents in human tumor xenografts (especially the CX-2 colon tumor) have stimulated renewed clinical interest in DON, the more readily available agent. DON mechanism of action, clinical pharmacology, previous clinical data, and current phase I studies are discussed.

Keywords

Lymphoma Leukemia Oncol Sarcoma Glutamine 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Catane R, Ovejera AA, Houchens DP, Von Hoff DD, Davis HL Jr, Wolpert MK, Rozencweig M, Muggia FM (1978) Rationale for further clinical trials with 6-dia- zo-5-oxo-L-norleucine (DON) (abstr). Proc Am Assoc Cancer Res and Am Soc Clin Oncol 19:317Google Scholar
  2. 2.
    Cooney DA, Jayaram HN, Milman HA, Homan ER, Pittillo R, Geran RI, Ryan J, Rosenbluth RJ (1976) DON, CONV and DONV-III, pharmacologic and toxicologic studies. Biochem Pharmacol 25:1859–1870PubMedCrossRefGoogle Scholar
  3. 3.
    Hill GJ, Larsen RR, Sas EM (1973) Cancer chemotherapy II. Results of 603 courses of therapy in 400 consecutive patients followed for 18-52 months. Oncology 27:137–152PubMedCrossRefGoogle Scholar
  4. 4.
    Li MC (1961) Management of chariocarcinoma and related tumors of the uterus and testis. Med Clin North Am 45:661–676PubMedGoogle Scholar
  5. 5.
    Livingston RB, Vendetti JM, Cooney DA, Carter SK (1970) Glutamine antagonists in chemotherapy, vol 8. Academic, New York, pp 62–83Google Scholar
  6. 6.
    Magill GB, Myers WPL, Reilly HC, Putnam RC, Magill JW, Sykes MP, Escher GC, Karnofsky GC, Burchenal JH (1957) Pharmacological and initial therapeutic observations on 6-diazo-5-oxo-L-norleucine (DON) in human neoplastic disease. Cancer 10:1138–1150PubMedCrossRefGoogle Scholar
  7. 7.
    Moore E, Hulbert R (1961) Biosynthesis of RNA cytosine and RNA purines; differential inhibition by 6-diazo-5-oxo-L-norleucine. Cancer Res 21:257–261PubMedGoogle Scholar
  8. 8.
    Moore EC, LePage GA (1957) In vivo sensitivity of normal and neoplastic mouse tissues to azaserine. Cancer Res 17:804–808PubMedGoogle Scholar
  9. 9.
    Ovejera AA, Houchens DP, Barker AD (1977) Chemotherapeutic sensitivity to anticancer agents of human tumor xenografts in athymic mice. Current Chemotherapy: Proc. 10th International Congress on Chemotherapy 2:1144–1146Google Scholar
  10. 10.
    Pittillo RF, Wooley C, Brockman RW, Ho DH (1971) Azotomycin (NSC-1566454): Biologic fate in mice and man. Cancer Chemother Rep 55:47–52PubMedGoogle Scholar
  11. 11.
    Prusiner S, Stadtman ER (eds) (1973) The enzymes of glutamine metabolism. Academic, New YorkGoogle Scholar
  12. 12.
    Rosenbluth RJ, Cooney DA, Jayaram HN, Milman HA, Homan ER (1976) DON, CONV, and DONV.-II, inhibition of L-asparaginase synthetase in vivo. Biochem Pharmacol 25:1851–1858PubMedCrossRefGoogle Scholar
  13. 13.
    Veterans Administration Cancer Chemotherapy Study Group (1959) A clinical study of the comparative effect of nitrogen mustard and DON in patients with bronchogenic carcinoma, Hodgkin’s disease, lymphosarcoma and melanoma. J Natl Cancer Inst 22:433–439Google Scholar
  14. 14.
    Weiss AJ, Mastrangelo MJ (1970) Phase I study of a combination of azotomycin + 5-FU in malignant disease. Cancer Chemother Rep 54:109–111PubMedGoogle Scholar
  15. 15.
    Weiss AJ, Ramirez G, Grage T, Strawitz J, Goldman L, Downing V (1968) Phase II study of azotomycin. Cancer Chemother Rep 52:611–614PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1980

Authors and Affiliations

  • D. L. Kisner
  • R. Catane
  • F. M. Muggia

There are no affiliations available

Personalised recommendations